Table of Contents Author Guidelines Submit a Manuscript
Autoimmune Diseases
Volume 2014, Article ID 201657, 11 pages
http://dx.doi.org/10.1155/2014/201657
Review Article

Treatment of Chronic Inflammatory Demyelinating Polyneuropathy: From Molecular Bases to Practical Considerations

1Department of Neurology, A.O.U. Maggiore di Novara, Amedeo Avogadro University, Corso Mazzini 18, 28100 Novara, Italy
2Department of Translational Medicine, Section of Neurology and Interdisciplinary Research Centre of Autoimmune Diseases (IRCAD), Via Solaroli 17, 28100 Novara, Italy
3Department of Translational Medicine, Amedeo Avogadro University, Via Solaroli 17, 28100 Novara, Italy

Received 29 September 2013; Accepted 13 November 2013; Published 14 January 2014

Academic Editor: Umberto Dianzani

Copyright © 2014 Paolo Ripellino et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Chronic inflammatory demyelinating polyneuropathy (CIDP) is an autoimmune disease of the peripheral nervous system, in which both cellular and humoral immune responses are involved. The disease is clinically heterogeneous with some patients displaying pure motor form and others also showing a variable degree of sensory dysfunction; disease evolution may also differ from patient to patient, since monophasic, progressive, and relapsing forms are reported. Underlying such clinical variability there is probably a broad spectrum of molecular dysfunctions that are and will be the target of therapeutic strategies. In this review we first explore the biological bases of current treatments and subsequently we focus on the practical management that must also take into account pharmacoeconomic issues.